Clinical Trial

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
JWCAR239 is a CD19/CD20 CAR-T product. This trial is intended to evaluate the safety, PK/PD and efficacy of JWCAR239 in patients with B Cell Non-Hodgkin Lymphoma (B-NHL)
Trial Details
NCT Number NCT07024147
Lead Sponsor Peking University Cancer Hospital & Institute
Collaborators: Shanghai JW Therapeutics Co., Ltd.
Conditions B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma, Follicular Lymphoma, Marginal Zone B Cell Lymphoma, Mantle Cell Lymphoma (MCL)
Enrollment 20 participants
Start Date 2025-07-01
Primary Completion 2027-07-01 (estimated)
Study Completion 2030-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-17